Evidence map›Paper›PMID 30940668›Full record

ArticleBMJ case reports2019

Tc-99m HYNIC-TOC scintigraphy in dedifferentiated thyroid cancer.

Kanhaiyalal Agrawal, P Sai Sradha Patro, C Preetam

Abstract readCase Reports
In one paragraph

Article in BMJ case reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Kanhaiyalal AgrawalNuclear Medicine, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India.
P Sai Sradha PatroNuclear Medicine, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India.
C PreetamENT, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is literature evidence showing utility of somatostatin receptor (SSTR) positron emission tomography-CT (PET-CT) imaging in differentiated thyroid cancer with Thyroglobulin Elevated and Negative Iodine Scan (TENIS). These patients are less benefited with I-131 therapy and surgery remains only curable option if disease could be localised. If surgery is not feasible, other therapeutic options are not promising. However, if these patients show strongly positive SSTR imaging, then possibility of peptide receptor radionuclide therapy may be explored. As SSTR PET-CT imaging is expensive and not widely available, Technetium-99m (Tc-99m) hydrazinonicotinyl-Tyr3-octreotide (HYNIC-TOC), which is a Single photon emission computed tomography (SPECT) tracer, can be used. We are documenting a case of raised serum thyroglobulin antibody and negative I-131 whole body scan with disease recurrence localised on Tc-99m HYNIC-TOC scan.

Indexed as

Organotechnetium CompoundsWhole Body ImagingAgedFemaleHumansIodine RadioisotopesNeoplasm Recurrence, LocalOctreotideThyroid Cancer, PapillaryThyroid NeoplasmsIodine RadioisotopesOctreotideOrganotechnetium Compoundstechnetium Tc 99m hydrazinonicotinyl-Tyr(3)-octreotidededifferentiatedendocrine systemthyroid cancerthyroid disease

Identifiers

PMID30940668
PMCPMC6453278

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.